Femasys inc. begins fembloc pivotal trial enrollment at uc davis medical center, a hub for innovation and groundbreaking research in health care for women

Atlanta, jan. 26, 2024 (globe newswire) -- femasys inc. (nasdaq: femy), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced that it has activated enrollment for its pivotal fembloc® trial at university of california, davis (“uc davis”) medical center in sacramento, california. the fembloc intratubal occlusion for transcervical permanent birth control (the “finale” trial) is being conducted to investigate the safety and efficacy of its investigational permanent birth control candidate, fembloc®. the fda-approved, multi-center trial is designed to address the high unmet need that exists for women seeking permanent birth control, for whom elective surgery currently remains the only option.
FEMY Ratings Summary
FEMY Quant Ranking